Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1b study of eftozanermin alfa with bortezomib + dexamethasone in relapsed or refractory multiple myeloma (Japan)
jRCT2041200103Phase 1Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- Dec 2020
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
01
Overview
Phase 1, open-label trial of eftozanermin in multiple myeloma (MM) (2 arms), sponsored by AbbVie Inc. Primary endpoints: Recommended Phase 2 Dose (RP2D) of eftozanermin alfa in combination with bortezomib and dexamethasone (Safety Lead-In Arm) and Objective Response Rate (ORR) (Dose Expansion Arm). Started Dec 2020; status: active, not recruiting.
02
Drugs
eftozanermin
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on jRCT2041200103.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041200103.